Primary Indication: Trigeminal Neuralgia
A Targeted Small Molecule Approach to Trigeminal Neuralgia
Developing DK-I-56-1, a differentiated GABA-A subtype-selective therapy designed to address the unmet need in trigeminal neuralgia.
Selective Mechanism: Rare GABA-A subtype targeting
Development Stage: Preclinical
Partnering Strategy: Milestone-driven value creation
Trigeminal Neuralgia
A severe neuropathic pain disorder affecting the trigeminal nerve, characterized by sudden, debilitating facial pain.
Sudden, Electric Pain
Episodes triggered by routine daily activities.
Severe Quality-of-Life Impact
Speaking, eating, and brushing teeth can trigger pain.
Referred to as the “Suicide Disease”
Reflecting extreme patient distress.
Current Treatment Landscape
No therapy approved by FDA for the treatment of trigeminal neuralgia.
Treatment relies on off-label anticonvulsants.
Carbamazepine as First-Line Standard
Often discontinued due to tolerability limitations.
Market Opportunity
1.5 B
Trigeminal Neuralgia TAM
Orphan neuropathic pain market
Current Treatment Landscape
Carbamazepine
- First-line off-label anticonvulsant
- Broad GABA modulation
- Non-selective CNS activity
- Established but imperfect efficacy
Tolerability & Discontinuation
- Sedation and dizziness
- Drug-drug interactions
- High discontinuation rates
No therapy approved by FDA for the treatment of trigeminal neuralgia.
Significant unmet need for a selective, better-tolerated alternative.
The Asset
DK-I-56-1
DK-I-56-1
A novel small-molecule therapy designed to selectively modulate a rare GABA-A receptor subtype involved in trigeminal pain signaling.
- Small-molecule neuromodulator
- Targets a rare GABA-A receptor subtype
- Designed for selective neural inhibition
Selective Targeting
Designed to act on a rare GABA-A subtype rather than broadly affecting CNS receptors.
Improved Tolerability Potential
Selective modulation may reduce sedation and CNS side effects associated with existing therapies.
Preclinical Evidence
Demonstrated activity in validated preclinical models of trigeminal pain.
Development Strategy
A focused path to clinical value creation.
Head-to-Head Preclinical Study
Comparing DK-I-56-1 directly against carbamazepine in validated trigeminal pain models.
Demonstrate Differentiation
Generate data supporting selective targeting and improved CNS tolerability.
Partner for Clinical Development
Advance toward licensing or strategic partnership following successful preclinical results.
Milestones and Use of Funds
The next value-creation phase.
600K Raise
Funding a focused preclinical validation program.
Head-to-Head Study
Execute preclinical comparison of DK-I-56-1 vs carbamazepine.
Data Generation
Establish differentiation in efficacy and tolerability.
Business Development
Engage potential pharmaceutical partners.
Value Inflection
Position the program for licensing or strategic partnership.
A clear partnering milestone.
Generating the data needed to support strategic collaboration.
Traction & Credibility
Early validation from industry and research partners.
Pharma Collaboration
Prior development partnership with a major pharmaceutical company.
CRO Continuity
The same CRO team that advanced the previous program remains engaged.
Partner Interest
Early conversations with potential pharmaceutical partners.
Positioned for strategic partnership.
Focused execution with experienced collaborators.
Leadership Team
Experienced scientists advancing targeted neurological therapeutics.
Michael Hendrickson
18 years in neuroscience & drug development; former Director of Preclinical Development and VP of Operations.
Joseph Beck, PhD
Neuroscientist and serial entrepreneur with three successful startups.
Barry Steiglitz, PhD
18 years pre-clinical research, including serving as principal investigator.
Alex Kasper
20 years of CFO experience, including 14 years in small pharmaceutical companies.
Proven track record in neuroscience ventures.
The team previously partnered a small-molecule asset to MapLight Therapeutics, contributing to $600M in fundraising and a $300M IPO.
Ready to explore the opportunity?
NeuroSolis is advancing a differentiated preclinical therapy for trigeminal neuralgia with expansion potential into migraine.
For investor inquiries, partnering discussions, or access to additional diligence materials, contact the NeuroSolis team below.
- Investor Inquiries
- Partnering Discussions
- Request Data Room Access